Bio-Omix
Bio-Omix is an early-diagnostics startup originating from UNAM's Faculty of Medicine, incubated within the InnovaUNAM system.
Position in SVTR
Snapshot 2026-10-28- Startup SignalsRankedof 2,177new
- Life SciencesRankedof 231
- Medical DiagnosisRankedof 23
About
Bio-Omix is an early-diagnostics startup originating from UNAM's Faculty of Medicine, incubated within the InnovaUNAM system. It has developed a fingerstick blood-based metabolic test using mass spectrometry combined with bioinformatics and machine learning to analyze patterns across lipids, amino acids and other molecules for early detection of complex diseases; its publicly reported lead application is early prediction of gestational diabetes (roughly three months earlier than conventional glucose-tolerance testing), and the team has also described progress on a preeclampsia application. Samples are stable at room temperature without a cold chain, with potential for at-home collection. The company has collaboration/validation relationships with Mexican institutions including the National Institute of Perinatology, the National Institute of Genomic Medicine (Inmegen), and Tecnológico de Monterrey's Tlalpan campus, and won the 2025 Pharmaceutical Innovation Prize from the Mexican Pharmaceutical Industry Council and the UNAM Foundation.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Bio-Omix
Bio-Omix is an early-diagnostics startup originating from UNAM's Faculty of Medicine, incubated within the InnovaUNAM system. It has developed a fingerstick blood-based metabolic test using mass spectrometry combined with bioinformatics and machine learning to analyze patterns across lipids, amino acids and other molecules for early detection of complex diseases; its publicly reported lead application is early prediction of gestational diabetes (roughly three months earlier than conventional glucose-tolerance testing), and the team has also described progress on a preeclampsia application. Samples are stable at room temperature without a cold chain, with potential for at-home collection. The company has collaboration/validation relationships with Mexican institutions including the National Institute of Perinatology, the National Institute of Genomic Medicine (Inmegen), and Tecnológico de Monterrey's Tlalpan campus, and won the 2025 Pharmaceutical Innovation Prize from the Mexican Pharmaceutical Industry Council and the UNAM Foundation.
—
United States
BusinessLatest roundTotal raisedDate- Network Bio
Links leading US academic biobanks into a unified research network producing training-ready multimodal datasets, and trains disease-specific AI foundation models on them that transfer across diseases, for disease detection, biomarker discovery and drug development
Undisclosed · $50M · 2026-08
$50M - Dinamo Biotechnologies
Blood cfDNA-based dynamic biomarker platform using AI/machine learning to decode molecular signals, providing patient stratification and molecular response monitoring for immunology drug developers
— - ClearNote Health
Develops blood-based early cancer screening tests and epigenomics software, using multi-omics analysis and machine learning to identify cancer earlier
Series D+ · $185M · 2026-05
$185M
China
BusinessLatest roundTotal raisedDate- DeepInformatics++
AI + digital pathology focused on core diagnostic needs: full-chain digital pathology department solutions incl. smart scanning, QC and multi-cancer analysis; develops the DeepPathAI pathology model.
Series C · 2026-07
— - 透彻未来
AI-based pathology image diagnosis services
Series A · $69M · 2024-06
$69M - 睿心医疗
Developer of AI precision diagnosis and treatment platforms for cardiovascular and cerebrovascular disease and of vascular interventional surgical robots.
Strategic · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- Neko Health
Provides full-body preventive health scans using sensors and blood analysis
Series C · $1.0B · 2026-07
$1.0B - Skin Analytics
AI tool that assists skin cancer detection by identifying skin lesions from images
Series B · $20M · 2025-04
$20M - Oxford Cancer Analytics
AI-based blood tests for cancer detection
Series A · $11M · 2025-01
$11M
Other / unspecified
BusinessLatest roundTotal raisedDate- Cent
Annual preventive health check protocol for consumers: whole-body MRI, low-dose CT, DEXA, ECG/ultrasound and 100+ blood and urine biomarkers, with an in-house AI system synthesizing multimodal imaging and biomarker data into health scores and risk ratings; runs its own clinical prevention centers in Bengaluru, Mumbai and Delhi NCR, and works with Siemens Healthineers to shorten scan times.
Equity + Debt · $5M · 2026-10
$5M - VOINOSIS
AI early screening for cognitive impairment/dementia and hearing health management using voice and auditory biomarkers, for healthcare providers and consumers.
— - Craif
Urine microRNA plus AI early cancer detection service (miSignal) and software medical device development for pancreatic cancer diagnosis
Series D+ · $88M · 2026-08
$88M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.